NSCLC

Jobs in Chemotherapy

Primary PEU

Primary causes

Primary CDI

Figure 1: Neuregulin signaling in chemotherapy-resistant lung cancer

NRG1 meets resistance Figure 1. Neuregulin signaling in chemotherapy-resistant lung cancer. Hegde et al. have uncovered a mechanism for chemotherapy resistance in non-small cell lung cancer (NSCLC). I...

International team reports first success of targeted therapy in most common genetic subtype of non-small cell lung cancer

A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combinatio...

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients

Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cel...

Two-Drug NSCLC Therapy Can't Boost Survival (CME/CE)

CHICAGO (MedPage Today) -- Survival in advanced non-small cell lung cancer (NSCLC) failed to improve with pemetrexed (Alimta) versus paclitaxel in combination chemotherapy, results of a large randomiz...

Lilly presents Phase 2 results for mAb lung cancer treatment

Eli Lilly and Company has presented new data from two Phase 2 ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC). Interim data for a study in chemotherapy-naive patient...

Boehringer submits afatinib MAA for NSCLC

Boehringer Ingelheim GmbH (Ingelheim, German) submitted an MAA to EMA for oral afatinib to treat EGFR-mutation-positive non-small cell lung cancer (NSCLC). In June, Boehringer reported that the dual i...

Bayer, Onyx Phase III NSCLC trial fails to meet primary endpoint

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that Phase III trial of Nexavar (sorafenib) in non-small cell lung cancer (NSCLC) patients did not meet primary endpoint of imp...

Lilly reports Phase II NSCLC data for ramucirumab

Eli Lilly and Co. (NYSE:LLY) reported data from a pair of open-label Phase II trials of ramucirumab to treat advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology me...

BRCA1: A New Predictive Genomic Marker for Chemotherapy and Radiotherapy 
of Non-small Cell Lung Cancer.

Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors worldwide. Chemotherapy and radiotherapy are the main methods in therapy of NSCLC. The identification and characterization...

Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.

BACKGROUND: The maximum standardized uptake value (SUV(max)) on (18)F-fluorodeoxyglucose-positron emission tomography ((18)F-FDG PET) within the primary tumor may predict outcome in patients with surg...

The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer.

Although oncological treatments are improving, the prognosis of non-small-cell lung cancer (NSCLC) patients has not. Several biomarkers related to prognosis have been evaluated, and M30 and M65 have b...

Multivariate Survival Analysis of Patients with Stage I NSCLC.

The effectiveness of adjuvant chemotherapy in providing survival advantage for stage I non-small cell lung cancer (NSCLC) patients, especially those with stage Ib NSCLC, remains to be determined. The...

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

Cancer stem cell (SC) chemoresistance may be responsible for the poor clinical outcome of non-small-cell lung cancer (NSCLC) patients. In order to identify the molecular events that contribute to NSCL...